

**NOTE FOR THE ATTENTION OF THE EU OBSERVATORY FOR THE SUPPLY OF RADIOISOTOPES FOR MEDICAL USE**  
**To Remik Baranczyk – ESA and Member of the EU Observatory**  
**And Kevin Charlton, OECD/NEA**

## COMMUNICATION REGARDING GLOBAL SUPPLY OF MO-99

Brussels, 1 July 2019

ANSTO has reported that it experienced a contamination incident at the new Australian Nuclear Medicine (ANM) Mo-99 production facility on 21 June. ANSTO is working closely with the Australian nuclear regulator ARPANSA to determine when production in ANM can commence.

ANSTO continued to produce Mo-99 at the former Mo-99 production facility known as Building 54 during the week after the ANM incident. However, regulatory approvals to operate Building 54 ceased on 30 June and work is being done to determine if it is possible to continue production in this facility. Until then, ANSTO has temporarily suspended all exports of bulk Mo-99 from Saturday 29 June.

ANSTO will provide a further update later this coming week.

IRE resumed production of Mo-99 and I-131 on 28 June as its two-week planned facility maintenance was successfully completed.

Nuclear Medicine Europe will continue to monitor the international Mo-99 and I-131 production situation and provide additional updates as necessary.

Bernard Ponsard,  
Chairman ERT

Ira Goldman,  
Chairman NMEu SoS WG

